ETON
What one share of Eton Pharmaceuticals holds
Pharmaceutical Preparations
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVITM, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Eton Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.88 |
|---|---|
| Profit | $0.47 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $0.54 |
| Cash and investments | $0.95 |
| Debt | $0.67 |
| Book value | $1.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$5.80 | $0.04 | −$1.31 | — | — |
| 2019 | — | −$1.03 | $0.06 | −$1.08 | — | $0.59 |
| 2020 | — | −$1.33 | $0.00 | −$1.07 | — | $0.73 |
| 2021 | $0.87 | −$0.08 | $0.00 | −$0.19 | — | $0.72 |
| 2022 | $0.85 | −$0.36 | $0.00 | $0.19 | — | $0.52 |
| 2023 | $1.23 | −$0.04 | $0.00 | $0.27 | — | $0.60 |
| 2024 | $1.51 | −$0.15 | $0.00 | $0.04 | — | $0.91 |
| 2025 | $2.97 | −$0.17 | $0.01 | $0.38 | — | $0.97 |